

ONCOLYTICS BIOTECH INC

Form 6-K

May 03, 2005

**Table of Contents**

---

---

**SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**Form 6-K**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934**

For the month of May 2005

Commission File Number 000-31062

**Oncolytics Biotech Inc.**

---

*(Translation of registrant's name into English)*

**Suite 210, 1167 Kensington Crescent NW  
Calgary, Alberta, Canada T2N 1X7**

---

*(Address of principal executive offices)*

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's home country), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If  Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82 - \_\_\_\_\_

---

---

---

**TABLE OF CONTENTS**

Signatures

FIRST QUARTER REPORT

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

BALANCE SHEETS

STATEMENTS OF LOSS AND DEFICIT

STATEMENTS OF CASH FLOWS

NOTES TO FINANCIAL STATEMENTS

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Oncolytics Biotech Inc.**  
(Registrant)

Date: May 3, 2005

By: /s/ Brad Thompson

\_\_\_\_\_  
Brad Thompson  
President & CEO

---

**Table of Contents**

**First Quarter Report**  
March 31, 2005

---

**Oncolytics Biotech Inc.**  
**TSX: ONC**  
**NASDAQ: ONCY**

---

**Table of Contents**

**FIRST QUARTER REPORT**

*For the quarter ended March 31, 2005*

**Letter to Shareholders**

To date in 2005, Oncolytics has received permission from regulatory authorities in the United Kingdom and the United States to begin three additional clinical studies with REOLYSIN® and strengthened its financial resources with the addition of approximately \$3.1 million from the exercise of warrants. The Company exited the first quarter of 2005 with cash resources of \$34.7 million which is expected to fund development activities through 2007.

In February 2005, Oncolytics received approval to begin a Phase I dose-escalation study in the U.K. to investigate local delivery of REOLYSIN® in combination with radiation for patients with advanced or metastatic solid tumours. The objective of the study is to determine the maximum tolerated dose and safety profile of REOLYSIN®, as well as to evaluate viral replication, immune response to the virus and any evidence of anti-tumour activity. The trial will include an additional group of patients once the maximum tolerated dose is identified. This is the second U.K. trial approval for Oncolytics, and will be the first study to be conducted in combination with another therapy.

Also in February 2005, Oncolytics received clearance to begin a Phase I/II clinical study in the U.S. to investigate the use of REOLYSIN® for patients with recurrent malignant gliomas (brain cancers) in the U.S. The primary objective of the study is to determine the maximum tolerated dose and safety profile of REOLYSIN®, as well as to evaluate viral replication, immune response to the virus and any evidence of anti-tumour activity. Similar to our combination radiation study, an additional group of patients will be treated at the maximum tolerated dose once it is identified.

In April 2005, subsequent to the quarter end, Oncolytics announced that it had received clearance to begin a Phase I study in the U.S. to investigate the systemic (intravenous) delivery of REOLYSIN® for patients with advanced or metastatic solid tumours. The primary objective of the study is to determine the maximum tolerated dose and safety profile of REOLYSIN®. Secondary objectives include the evaluation of viral replication, immune response to the virus and any evidence of anti-tumour activity.

Oncolytics is now conducting or has permission to commence five clinical trials investigating the use of REOLYSIN® in the United States, the United Kingdom and Canada.

With the planned clinical activity in 2005, Oncolytics expects to develop a more thorough understanding of the safety and efficacy of REOLYSIN® for various cancers, modes of administration, and in combination with other therapies.

Thank you for your support.

Brad Thompson, PhD  
President and CEO  
April 26, 2005

## **Table of Contents**

**April 26, 2005**

## **MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

This discussion and analysis should be read in conjunction with the unaudited financial statements of Oncolytics Biotech Inc. (Oncolytics or the Company) as at and for the three months ended March 31, 2005 and 2004, and should also be read in conjunction with the audited financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A) contained in Oncolytics' annual report for the year ended December 31, 2004. The financial statements have been prepared in accordance with Canadian generally accepted accounting principles (GAAP).

## **FORWARD-LOOKING STATEMENTS**

*The following discussion contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's belief as to the potential of REOLYSIN® as a cancer therapeutic, the Company's expectation regarding the adequacy of its existing capital resources, and the Company's expectations as to the success of its research and development programs in 2005 and beyond, future financial position, business strategy and plans for future operations, and statements that are not historical facts, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN® as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN®, uncertainties related to the research and development of pharmaceuticals, uncertainties related to competition, changes in technology, the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Forward-looking statements are based on assumptions, projections, estimates and expectations of management at the time such forward-looking statements are made, and such assumptions, projections, estimates and/or expectations could change or prove to be incorrect or inaccurate. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.*

## **OVERVIEW**

### **Oncolytics Biotech Inc. is a Development Stage Company**

Since its inception in April of 1998, Oncolytics Biotech Inc. (the Company) has been a development stage company and has focused its research and development efforts on the development of REOLYSIN®, its potential cancer therapeutic. The Company has not been profitable since its inception and expects to continue to incur substantial losses from its research and development. The Company does not expect to generate significant revenues until, if and when, its cancer product becomes commercially viable.

### **General Risk Factors**

Prospects for biotechnology companies in the research and development stage should generally be regarded as speculative. It is not possible to predict, based upon studies in animals, or early studies in humans, whether a new therapeutic will ultimately prove to be safe and effective in humans, or whether necessary and sufficient data can be



developed through the clinical trial process to support a successful product application and approval.

---

**Table of Contents**

If a product is approved for sale, product manufacturing at a commercial scale and significant sales to end users at a commercially reasonable price may not be successful. There can be no assurance that the Company will generate adequate funds to continue development, or will ever achieve significant revenues or profitable operations. Many factors (e.g. competition, patent protection, appropriate regulatory approvals) can influence the revenue and product profitability potential.

In developing a product for approval, the Company will rely upon its employees, contractors, consultants and collaborators and other third party relationships, including the ability to obtain appropriate product liability insurance. There can be no assurance that these reliances and relationships will continue as required.

In addition to developmental and operational considerations, market prices for securities of biotechnology companies generally are volatile, and may or may not move in a manner consistent with the progress being made by the Company.

**Highlights**

During the first quarter of 2005, the Company's net loss was \$2,377,049 compared to \$2,676,236 for the first quarter of 2004. The decrease in the Company's net loss primarily reflects a decrease in manufacturing and related process development expenses. In the first quarter of 2004, the Company was incurring expenses associated with manufacturing technology transfer and process development costs. In the first quarter of 2005, these costs have been reduced with the focus on product manufacturing.

The reduction in manufacturing and related process development costs have been offset by an increase in the Company's clinical trial expenses associated with its ongoing and recently approved clinical trial studies.

The Company continued to receive cash proceeds from the exercise of warrants from previously closed financings. In the first quarter of 2005, \$3,075,887 was received from the exercise of warrants. The Company exited the first quarter of 2005 with cash and cash equivalents (including short-term investments) of \$34,712,838 compared to \$33,919,223 as at December 31, 2004.

**RESULTS OF OPERATIONS**

Net loss for the three month period ended March 31, 2005 was \$2,377,049 compared to \$2,676,236 for 2004. The changes in the Company's net loss were due to the following:

**Research and Development Expenses ( R&D )**

	<b>2005</b>	<b>2004</b>
	<b>\$</b>	<b>\$</b>
Manufacturing and related process development expenses	<b>812,214</b>	1,376,430
Clinical trial expenses	<b>232,348</b>	125,645
Pre-clinical trial and research collaboration expenses	<b>236,190</b>	178,960
Other R&D expenses	<b>349,512</b>	273,362
Research and development expenses	<b>1,630,264</b>	1,954,397

For the first quarter of 2005, R&D decreased to \$1,630,264 compared to \$1,954,397 for the first quarter of 2004. The decrease in R&D was due to the following:

---

**Table of Contents*****Manufacturing & Related Process Development Expenses ( M&P )***

	<b>2005</b>	<b>2004</b>
	<b>\$</b>	<b>\$</b>
Product manufacturing expenses	<b>775,635</b>	857,269
Technology transfer expenses		167,880
Process development expenses	<b>36,579</b>	351,281
Manufacturing and related process development expenses	<b>812,214</b>	1,376,430

During the first quarter of 2005, the Company's product manufacturing expenses decreased to \$775,635 compared to \$857,269 for the first quarter of 2004. In January 2005, the Company extended its manufacturing agreement with Cobra Biomanufacturing Plc (Cobra) to provide additional cGMP production and clinical trial supply material for the Company's clinical trial program. The value of this agreement is in excess of \$1,725,000 (contracted in pounds sterling) as it contemplates multiple production runs over the remainder of 2005. These production runs will be used to supply the Company's existing and planned clinical trial program, and collaborative research program.

In the first quarter of 2004, the Company entered into an agreement with Cobra to commence the manufacturing of REOLYSIN® and therefore incurred expenses associated with the transfer of the Company's manufacturing technology. This transfer was completed in 2004; consequently the Company did not incur technology transfer expenses in the first quarter of 2005.

During the first quarter of 2005, the Company incurred process development expenses of \$36,579 compared to \$351,281 in the first quarter of 2004. Process development activity on the existing manufacturing process was largely completed in 2004. The Company expects to continue to incur process development costs as it looks to begin studies to continue to improve process yields.

***Clinical Trial Programs***

	<b>2005</b>	<b>2004</b>
	<b>\$</b>	<b>\$</b>
Direct clinical trial expenses	<b>232,348</b>	125,645

During the first quarter of 2005, the Company's direct clinical trial expenses increased to \$232,348 compared to \$125,645 in the first quarter of 2004. This increase reflects enrollment in the UK systemic clinical study which had not started in the first quarter of 2004, and initiation costs associated with newly approved studies.

The Company expects its clinical trial expenses to continue to increase for the remainder of 2005. Patient enrollment for the U.K. radiation co-therapy clinical trial and the two U.S. clinical trials is expected to commence in 2005. The Company expects to continue with patient enrollment in the U.K. systemic clinical trial and the Canadian malignant glioma clinical trial.

***Pre-Clinical Trial and Research Collaboration Expenses***

	<b>2005</b>	<b>2004</b>
	<b>\$</b>	<b>\$</b>
Research collaboration expenses	<b>183,423</b>	46,419
Pre-clinical trial expenses	<b>52,767</b>	132,541
Pre-clinical trial expenses and research collaborations	<b>236,190</b>	178,960

During the first quarter of 2005, the Company's research collaboration expenses increased to \$183,423 compared to \$46,419 in the first quarter of 2004. The Company incurs research collaboration expenses as it continues to investigate the interaction of the immune system and the reovirus, the use of the reovirus as a co-therapy with existing chemotherapeutics and radiation and the possibility of new uses for the reovirus in therapy. These expenses will fluctuate from period to period depending on the progress of these collaborations.

---

**Table of Contents**

During the first quarter of 2005 the Company's pre-clinical trial expenses decreased to \$52,767 compared to \$132,541 in the first quarter of 2004. The frequency of the Company's pre-clinical studies change from period to period as the Company moves through its clinical trial program. As well, depending on the results of the Company's research collaborations, the Company may increase its pre-clinical trial activity.

**Operating Expenses**

	<b>2005</b>	<b>2004</b>
	<b>\$</b>	<b>\$</b>
Public company related expenses	<b>518,104</b>	462,018
Office expenses	<b>238,212</b>	234,784
Operating expenses	<b>756,316</b>	696,802

During the first quarter of 2005, the Company's operating expenses increased to \$756,316 compared to \$696,802 in the first quarter of 2004. The Company's regulatory filing fees associated with its annual report were incurred in the first quarter of 2005 while in 2004 these costs were incurred in the second quarter of 2004.

**Commitments**

As at March 31, 2005, the Company has committed to payments totaling \$1,027,548 for activities primarily related to product manufacturing and ongoing research collaborations. The Company anticipates that these committed payments will occur in 2005. All of these committed payments are considered to be part of the Company's normal course of business.

**LIQUIDITY AND CAPITAL RESOURCES****Liquidity**

As at March 31, 2005, the Company had cash and cash equivalents (including short-term investments) and working capital positions (current assets less current liabilities) of \$34,712,838 and \$33,902,264 respectively compared to \$33,919,223 and \$33,268,097 respectively for December 31, 2004. The increase in the first quarter of 2005 reflects the cash inflow from the exercise of warrants that raised \$3,075,887. Cash outflows during the period arose from research and development expenses, operational expenses, and intellectual property expenditures.

The Company desires to maintain adequate cash and short-term investment reserves to support its planned activities which include its clinical trial program, production manufacturing, and its intellectual property expansion and protection. The Company presently anticipates that its average cash usage for 2005 will be approximately \$1,000,000 per month and its existing capital resources are adequate to fund its current plans for research and development activities through 2007. Factors that will affect the Company's anticipated monthly burn rate include, but are not limited to, the number of manufacturing runs required to supply its clinical trial program and the cost of each run, the number of clinical trials ultimately approved, the timing of patient enrollment in the approved clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of the U.S. National Cancer Institute's R&D activity, and the level of pre-clinical activity undertaken.

In the event that the Company chooses to seek additional capital, the Company will look to fund additional capital requirements primarily through the issue of additional equity. The Company recognizes the challenges and uncertainty inherent in the capital markets and the potential difficulties it might face in raising additional capital. Market prices and market demand for securities in biotechnology companies are volatile and there are no assurances that the Company would have the ability to raise funds when required.

---

**Table of Contents****Capital Expenditures**

During the first quarter of 2005 the Company spent \$297,396 on intellectual property compared to \$130,540 in the first quarter of 2004. The difference relates to variances in filing fees on existing patent applications.

**Investing Activities**

Under its Investment Policy, the Company is permitted to invest in short-term instruments with a rating no less than R-1 (DBRS) with terms less than two years. As at March 31, 2005, the Company invested \$26,249,162 under this policy and is currently earning interest at an effective annual rate of 3.22%.

**SUMMARY OF QUARTERLY RESULTS**

The following unaudited quarterly information is presented in thousands of dollars except for per share amounts:

	2005		2004		2003			
	March	Dec.	Sept.	June	March	Dec.	Sept.	June
Revenue <sup>(1)</sup>	245	205	194	183	117	127	102	41
Net loss <sup>(2),(5)</sup>	2,377	3,992	3,096	3,192	2,676	1,696	1,823	3,911
Basic and diluted loss per common share <sup>(2),(5)</sup>	\$ 0.07	\$ 0.14	\$ 0.11	\$ 0.11	\$ 0.10	\$ 0.06	\$ 0.07	\$ 0.17
Total assets <sup>(3),(6)</sup>	40,519	39,489	29,471	31,221	25,435	26,051	21,532	18,815
Total cash <sup>(4),(6)</sup>	34,713	33,919	23,806	25,522	20,298	20,753	15,843	13,486
Total long-term debt <sup>(7)</sup>	150	150	150	150	150	150	150	150
Cash dividends declared <sup>(8)</sup>	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil

- (1) Revenue is comprised of interest income and income from short term investments.
- (2) Included in net loss and net loss per share between March 2005 and June 2003 is a quarterly gain (loss) on sale of investment of \$765, \$nil, (\$12,817), (\$646), \$47,648, \$264,453, \$nil, and (\$2,156,685), respectively.
- (3) Subsequent to the acquisition of the Company by SYNSORB in April 1999, the Company applied push down accounting. See note 2 to the audited financial statements for 2004.
- (4) Included in total cash are cash and cash equivalents plus short-term investments.
- (5) Included in net loss and loss per common share between March 2005 and June 2003 are quarterly stock based compensation expenses of \$13,375, \$1,870,596, \$48,878, \$734,670 \$5,426, \$490,364, \$437,554 and \$68,318, respectively.
- (6) The Company issued 768,972 commons shares for cash proceeds of \$3,075,887 in 2005 (2004 4,685,775 common shares for \$23,495,961 and 2003 5,062,978 common shares for \$16,004,981). In addition, 21,459 common shares were issued in September 2004 as partial consideration for the cancellation of a portion of the Company's contingent payments (see note 9 to the audited financial statements for 2004).
- (7) The long-term debt recorded represents repayable loans from the Alberta Heritage Foundation.
- (8) The Company has not declared or paid any dividends since incorporation.

**OTHER MD&A REQUIREMENTS**

The Company has 32,686,748 common shares outstanding at April 26, 2005. If all of the Company's warrants and options were exercised the Company would have 38,003,358 common shares outstanding.



Additional information relating to the Company is available on SEDAR at [www.sedar.com](http://www.sedar.com).

---

**Table of Contents**

Interim Unaudited Financial Statements

**Oncolytics Biotech Inc.**

March 31, 2005

---

**Table of Contents****Oncolytics Biotech Inc.****BALANCE SHEETS**

As at

	<b>March 31, 2005 \$ (unaudited)</b>	<b>December 31, 2004 \$ (unaudited)</b>
<b>ASSETS</b>		
<b>Current</b>		
Cash and cash equivalents	<b>8,463,676</b>	12,408,516
Short-term investments <i>[note 3]</i>	<b>26,249,162</b>	21,510,707
Accounts receivable	<b>40,584</b>	47,767
Prepaid expenses	<b>416,127</b>	250,365
	<b>35,169,549</b>	34,217,355
<b>Capital assets</b>	<b>5,349,332</b>	5,259,286
<b>Investments <i>[note 3]</i></b>		12,000
	<b>40,518,881</b>	39,488,641
<b>LIABILITIES AND SHAREHOLDERS EQUITY</b>		
<b>Current</b>		
Accounts payable and accrued liabilities	<b>1,267,285</b>	949,258
<b>Alberta Heritage Foundation loan</b>	<b>150,000</b>	150,000
<b>Shareholders equity</b>		
Share capital <i>[note 2]</i>		
Authorized: unlimited number of common shares		
Issued: 32,684,468 (December 31, 2004 - 31,915,496)	<b>70,047,404</b>	66,643,325
Warrants <i>[note 2]</i>	<b>3,019,438</b>	3,347,630
Contributed surplus	<b>6,362,514</b>	6,349,139
Deficit	<b>(40,327,760)</b>	(37,950,711)
	<b>39,101,596</b>	38,389,383
	<b>40,518,881</b>	39,488,641

*See accompanying notes*

---

Table of Contents**Oncolytics Biotech Inc.****STATEMENTS OF LOSS AND DEFICIT**

For the three month periods ended March 31,

	<b>2005</b>	<b>2004</b>	<b>Cumulative from inception on April 2, 1998 to March 31, 2005</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>
	<i>(unaudited)</i>	<i>(unaudited)</i>	<i>(unaudited)</i>
<b>Revenue</b>			
Rights revenue			310,000
Interest income	<b>244,658</b>	117,356	3,030,398
	<b>244,658</b>	117,356	3,340,398
<b>Expenses</b>			
Research and development	<b>1,630,264</b>	1,954,397	25,156,792
Operating	<b>756,316</b>	696,802	10,762,110
Stock based compensation <i>[note 2]</i>	<b>13,375</b>	5,426	3,711,370
Foreign exchange loss	<b>16,566</b>	5,592	376,536
Amortization	<b>205,951</b>	179,023	2,867,797
	<b>2,622,472</b>	2,841,240	42,874,605
<b>Loss before the following:</b>	<b>2,377,814</b>	2,723,884	39,534,207
<b>Gain on sale of BCY LifeSciences Inc. <i>[note 3]</i></b>	<b>(765)</b>	(47,648)	(299,403)
<b>Loss on sale of Transition Therapeutics Inc.</b>			2,156,685
<b>Loss before taxes</b>	<b>2,377,049</b>	2,676,236	41,391,489
<b>Capital tax</b>			51,271
<b>Future income tax recovery</b>			(1,115,000)

<b>Net loss for the period</b>	<b>2,377,049</b>	2,676,236	40,327,760
<b>Deficit, beginning of period</b>	<b>37,950,711</b>	24,994,592	
<b>Deficit, end of period</b>	<b>40,327,760</b>	27,670,828	40,327,760
<b>Basic and diluted loss per share</b>	<b>0.07</b>	0.10	
<b>Weighted average number of shares (basic and diluted)</b>	<b>32,267,528</b>	27,255,740	

*See accompanying notes*

---

Table of Contents**Oncolytics Biotech Inc.****STATEMENTS OF CASH FLOWS**

For the three month periods ended March 31,

	<b>2005</b>	<b>2004</b>	<b>Cumulative from inception on April 2, 1998 to March 31, 2005</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>
	<i>(unaudited)</i>	<i>(unaudited)</i>	<i>(unaudited)</i>
<b>OPERATING ACTIVITIES</b>			
Net loss for the period	<b>(2,377,049)</b>	(2,676,236)	(40,327,760)
Deduct non-cash items			
Amortization	<b>205,951</b>	179,023	2,867,797
Stock based compensation	<b>13,375</b>	5,426	3,711,370
Gain on sale of BCY LifeSciences Inc.	<b>(765)</b>	(47,648)	(299,403)
Foreign exchange loss	<b>30,479</b>		296,461
Cancellation of contingent payment obligation settled in common shares			150,000
Loss on sale of Transition Therapeutics Inc.			2,156,685
Future income tax recovery			(1,115,000)
Net changes in non-cash working capital	<b>166,445</b>	1,140,583	674,678
	<b>(1,961,564)</b>	(1,398,852)	(31,885,172)
<b>INVESTING ACTIVITIES</b>			
Purchase of intellectual property	<b>(297,396)</b>	(130,540)	(3,921,031)
Purchase of other capital assets	<b>(5,598)</b>	(1,598)	(531,800)
Purchase of short-term investments	<b>(5,207,879)</b>	(245,266)	(30,096,666)
Redemption of short-term investments	<b>443,745</b>	1,000,000	3,557,745
Investment in BCY LifeSciences Inc.	<b>7,965</b>	131,650	464,602
Investment in Transition Therapeutics Inc.			2,532,343
	<b>(5,059,163)</b>	754,246	(27,994,807)
<b>FINANCING ACTIVITIES</b>			
Alberta Heritage Foundation loan			150,000
Proceeds from exercise of warrants and stock options	<b>3,075,887</b>	944,745	14,658,168
Proceeds from private placements			22,741,983

Proceeds from public offerings			30,793,504
	<b>3,075,887</b>	944,745	68,343,655
<b>Increase (decrease) in cash and cash equivalents during the period</b>	<b>(3,944,840)</b>	300,139	8,463,676
<b>Cash and cash equivalents, beginning of the period</b>	<b>12,408,516</b>	2,641,127	
<b>Cash and cash equivalents, end of the period</b>	<b>8,463,676</b>	2,941,266	8,463,676

*See accompanying notes*

---



Table of Contents**Oncolytics Biotech Inc.****NOTES TO FINANCIAL STATEMENTS**March 31, 2005 (*unaudited*)**1. ACCOUNTING POLICIES**

These unaudited interim financial statements do not include all of the disclosures included in the Company's annual financial statements. Accordingly, these unaudited interim financial statements should be read in conjunction with the Company's most recent annual financial statements. The information for as at and for the year ended December 31, 2004 has been derived from the Company's audited financial statements.

The accounting policies used in the preparation of these unaudited interim financial statements conform with those used in the Company's most recent annual financial statements.

**2. SHARE CAPITAL****Authorized:**

Unlimited number of common shares

<b>Issued:</b>	<b>Shares</b>		<b>Warrants</b>	
	<b>Number</b>	<b>Amount \$</b>	<b>Number</b>	<b>Amount \$</b>
Balance, December 31, 2003	27,208,262	44,712,589	3,258,155	1,598,250
Issued for cash pursuant to April 7, 2004 private placement	1,077,100	5,924,050	646,260	1,028,631
Issued for cash pursuant to pursuant to November 23, 2004 public offering	1,504,000	8,693,120	864,800	1,521,672
Issued pursuant to cancellation of contingent payment	21,459	150,000		
Exercise of warrants	1,907,175	8,178,546	(1,907,175)	(798,096)
Expired warrants		2,827	(6,700)	(2,827)
Exercise of options	197,500	778,951		
Share issue costs		(1,796,758)		
Balance, December 31, 2004	31,915,496	66,643,325	2,855,340	3,347,630
Exercise of warrants	768,972	3,404,079	(768,972)	(328,192)
<b>Balance March 31, 2005</b>	<b>32,684,468</b>	<b>70,047,404</b>	<b>2,086,368</b>	<b>3,019,438</b>

**Table of Contents****Oncolytics Biotech Inc.****NOTES TO FINANCIAL STATEMENTS**March 31, 2005 (*unaudited*)

The following table summarizes the Company's outstanding warrants as at March 31, 2005:

<b>Exercise Price</b>	<b>Outstanding, Beginning of the Period</b>	<b>Granted During the Period</b>	<b>Exercised During the Period</b>	<b>Expired During the Period</b>	<b>Outstanding, End of Period</b>	<b>Weighted Average Remaining Contractual Life (years)</b>
\$4.00	768,972		768,972			
\$5.00	45,558				45,558	0.04
\$6.25	529,750				529,750	0.04
\$7.00	107,710				107,710	0.50
\$7.06	112,800				112,800	1.15
\$7.75	538,550				538,550	0.50
\$8.00	752,000				752,000	2.65
	2,855,340		768,972		2,086,368	1.18

**Stock Based Compensation**

As the Company is following the fair value based method of accounting for stock options, the Company recorded compensation expense of \$13,375 (March 31, 2004 \$5,426) for the period with respect to the vesting of options issued in prior periods with an offsetting credit to contributed surplus.

**3. INVESTMENTS**

During the three month period ending March 31, 2005, the Company sold 120,000 (March 31, 2004 676,945) of its BCY LifeSciences Inc. ( BCY ) shares for net cash proceeds of \$7,965 (March 31, 2004 \$131,650) recording a gain on sale of investment of \$765 (March 31, 2004 \$47,648). As at March 31, 2005, the Company still owned 80,000 common shares of BCY with a book value of \$4,800. These common shares will be released from escrow in February 2006, consequently the remaining investment in BCY has been reclassified as a short-term investment.

**4. COMPARATIVE FIGURES**

Certain comparative figures have been reclassified to conform with the current period's presentation.

**5. SUBSEQUENT EVENT**

On April 14, 2005, 529,750 warrants with an exercise price of \$6.25 and 43,278 broker warrants with an exercise price of \$5.00 expired unexercised. These warrants were issued as part of the Company's October 14, 2003 public offering.

---

**Table of Contents**

**Shareholder Information**

For public company filings please go to  
www.sedar.com or contact us at:

Oncolytics Biotech Inc.  
Suite 210, 1167 Kensington Crescent NW  
tel: 403.670.7377 fax: 403.283.0858  
Calgary, Alberta, Canada T2N 1X7  
www.oncolyticsbiotech.com

**Officers**

**Brad Thompson, PhD**

Chairman, President and CEO

**Doug Ball, CA**

Chief Financial Officer

**Matt Coffey, PhD**

Chief Scientific Officer

**George Gill, MD**

Senior Vice President, Clinical and Regulatory Affairs

**Directors**

**Brad Thompson, PhD**

Chairman, President and CEO, Oncolytics Biotech Inc.

**Doug Ball, CA**

CFO, Oncolytics Biotech Inc.

**William. A. Cochrane, OC, MD**

Biotech Consultant

**Jim Dinning**

Chairman, Western Financial Group

**J. Mark Lievonen**

President, Sanofi Pasteur Limited

**Tony Noujaim, PhD**

CEO and Chairman, ViRexx Medical Corp.

**Bob Schultz, FCA**

Chairman, Rockwater Capital Corporation

**Fred Stewart, QC**

President, Fred Stewart and Associates Inc.